Institute of Pathology

MONITORING OF GENERAL IMMUNE STATUS AND SARS-COV-2 REACTIVE T-CELL AND HUMORAL IMMUNITY FACILITATES THE CLINICAL DECISION IN A SEVERE SARS-COV-2-ASSOCIATED PNEUMONIA, MENINGOENCEPHALITIS AND GASTROENTERITIS IN A PANCREAS-KIDNEY TRANSPLANT PATIENT (2020) Babel N, Stervbo U, Seibert F, Bauer F, Anft M, Rohn B, Winnekendonk G, et al. Conference contribution ALLOGRAFT INFILTRATION AND MENINGOENCEPHALITIS BY SARS-COV-2 IN A PANCREAS-KIDNEY TRANSPLANT RECIPIENT (2020) Doevelaar A, Seibert F, Bauer F, Stervbo U, Anft M, Rohn B, Winnekendonk G, et al. Conference contribution INTERLEUKIN-21-A NEW PLAYER IN ALLOGRAFT REJECTION? (2020) Steines L, Friedmann J, Schuster A, Poth H, Amann KU, Banas B, Bergler T Conference contribution DISRUPTION OF TFH:B CELL CROSSTALK PREVENTS ANTIBODY-MEDIATED REJECTION IN AN EXPERIMENTAL KIDNEY TRANSPLANT MODEL (2020) Steines L, Poth H, Schuster A, Amann KU, Banas B, Bergler T Conference contribution Influence of the Family Anamnesis of Breast or Ovarian Cancer on the pathological Complete Remission and the Prognosis in Patients with Breast Cancer after neoadjuvant Chemotherapy (2020) Gaß P, Haberle L, Hein A, Jud S, Lux MP, Hack C, Emons J, et al. Conference contribution Accuracy of vulvoscopic findings in detecting early vulvar neoplasia (2020) Stuebs FA, Mehlhorn G, Gaß P, Schulmeyer C, Adler W, Strehl J, Hartmann A, et al. Conference contribution Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup (2020) Emons J, Fasching P, Wunderle M, Heindl F, Rieger J, Horn F, Pelzer G, et al. Conference contribution Accuracy of colposcopic findings in detecting vaginal intraepithelial neoplasia: a retrospective study (2020) Stuebs FA, Adler W, Beckmann M, Gaß P, Hartmann A, Mehlhorn G, Renner SK, et al. Conference contribution Mammographic Density and Prognosis in Patients with primary Breast Cancer - Loss of Risk with increasing Age (2020) Heindl F, Fasching P, Hein A, Hack C, Heusinger K, Gaß P, Schulz-Wendtland R, et al. Conference contribution Progression-free survival and overall survival in patients with advanced her2-positive breast cancer treated with trastuzumab emtansine (T-dm1) after previous treatment with pertuzumab (2020) Michel LL, Hartkopf AD, Fasching P, Kolberg HC, Hadji P, Tesch H, Häberle L, et al. Journal article